Rising costs, tighter regulations, and investor pressure are forcing major shifts across the healthcare sector. While the rest of the market is approaching bear market territory, the biotech sector has been in a nuclear winter for some time now. Insurers and providers are being pushed to adapt—or risk falling behind.
Once hailed as a bold innovator reshaping American healthcare, CVS Health now finds itself in the middle of a high-stakes turnaround. After a bruising 2024 marked by financial shortfalls, mounting investor pressure, and executive upheaval, the company is shedding underperforming units, slashing costs, and bringing in new leadership. The big question now is whether this healthcare giant can stabilize its core business and rebuild investor confidence, or if even more radical change is on the horizon.